Oppenheimer analyst Jeff Jones downgraded Y-mAbs Therapeutics (YMAB) without a price target to Perform from Outperform after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in cash.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Hold Rating Issued Amidst SERB Pharmaceuticals’ Acquisition of Y-mAbs Therapeutics
- Y-mAbs Therapeutics downgraded to Hold from Buy at Truist
- Y-mAbs Therapeutics downgraded to Hold from Buy at Brookline
- Y-mAbs Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
- Y-mAbs Therapeutics downgraded to Hold from Buy at Clear Street